Squishy gel could include a chemical compound capable of helping repair, restore or regenerate cartilage in a joint.
PR-COIN Initiative Takes Aim at Juvenile Idiopathic Arthritis
The Pediatric Rheumatology Care and Outcomes Improvement Network uses clinical evidence and a network of collaborators to improve outcomes for children with JIA
Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
A new study confirms that the use of immunosuppressive drugs is associated with a reduced risk of vision loss in patients with juvenile idiopathic arthritis-related uveitis.
Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis
In patients with simultaneous systemic and arthritic components of systemic juvenile idiopathic arthritis (SJIA), these components appear to be related mechanistically. Moreover, the inflammatory pathways of SJIA appear to be distinct from those seen in polyarticular JIA.
Systemic Juvenile Idiopathic Arthritis
Changing treatment paradigms in the biologic era
Patient Fact Sheet: Juvenile Idiopathic Arthritis
Several types of arthritis fall under the JIA heading. This inflammation begins before patients reach the age of 16 years, and may involve one or many joints and cause other symptoms such as fevers, rash, and eye inflammation.
CARRA
Working for Children with Rheumatic Diseases
A Day in the Life of Gay Kuchta, OT
Treating children with rheumatologic diseases takes a unique approach. “You shouldn’t treat them as little adults,” says Gay Kuchta, OT, who works in pediatrics at the Mary Pack Arthritis Program at Vancouver Hospital in British Columbia. “They take special consideration.”